AEON Biopharma issues corporate presentation with no new material facts

AEON Biopharma, Inc.

Presentation dated January 2026 made available on IR website (Item 7.01).
Reiterates ABP-450 as biosimilar to BOTOX, aiming to be first complete therapeutic alternative.
No financial or clinical data disclosed; no guidance or milestones provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.